Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles

Pharmaceutical Research

Volumn 30, Issue 8, 2013, Pages 1956-1967

  Gullotti, Emily ^a   Park, Joonyoung ^b   Yeo, Yoon ^a,b,c  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c Korea Institute of Science and Technology   (South Korea)

Author keywords

dopamine polymerization; PEG cleavage; polymeric nanoparticles; surface modification; TAT peptide

Indexed keywords

AVIDIN; BIOTIN; DOPAMINE; GELATINASE A; GOLD NANOPARTICLE; LIPOSOME; MACROGOL; MATRIX METALLOPROTEINASE; NANOPARTICLE; NUCLEOPHILE; PACLITAXEL; PLASMID DNA; POLYGLACTIN; SMALL INTERFERING RNA; TRANSACTIVATOR PROTEIN; UROKINASE;

ARTICLE; CANCER CELL; CONFOCAL MICROSCOPY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INCUBATION TIME; NANOENCAPSULATION; OVARY CANCER; POLYMERIZATION; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CELL LINE, TUMOR; DRUG CARRIERS; FEMALE; GENE PRODUCTS, TAT; HUMANS; INDOLES; LACTIC ACID; MATRIX METALLOPROTEINASE 2; MOLECULAR SEQUENCE DATA; NANOPARTICLES; OVARIAN NEOPLASMS; PACLITAXEL; PEPTIDES; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID; POLYMERS;

EID: 84879795014     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1039-y     Document Type: Article

References (42)

1. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12):6387-92.
2. Gabizon AA, Shmeeda H, Zalipsky S. Pros and cons of the liposome platform in cancer drug targeting. J Liposome Res. 2006;16(3):175-83.
3. Yokoyama M. Drug targeting with nano-sized carrier systems. J Artif Organs. 2005;8(2):77-84.
4. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751-60.
5. Wang M, Thanou M. Targeting nanoparticles to cancer. Pharmacol Res. (2010) 62(2):90-9
6. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6(4):1041-51.
7. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. Mol Membr Biol. 2010;27(7):286-98.
8. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci U S A. 2008;105(7):2586-91.
9. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials. 2007;28(5):869-76.
10. Montcourrier P, Silver I, Farnoud R, Bird I, Rochefort H. Breast cancer cells have a high capacity to acidify extracellular milieu by a dual mechanism. Clin Exp Metastasis. 1997;15(4):382-92.
11. Swallow CJ, Grinstein S, Rotstein OD. A vacuolar type h(+)-atpase regulates cytoplasmic ph in murine macrophages. J Biol Chem. 1990;265(13):7645-54.
12. Niidome T, Ohga A, Akiyama Y, Watanabe K, Niidome Y, Mori T, et al. Controlled release of peg chain from gold nanorods: targeted delivery to tumor. Bioorg Med Chem. 2010;18(12):4453-8.
13. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2(3):161-74.
14. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Inhibition of matrix metalloproteinase-2 secretion and invasion by human ovarian cancer cell line sk-ov-3 with lysine, proline, arginine, ascorbic acid and green tea extract. J Obstet Gynaecol Res. 2006;32(2):148-54.
15. Rabinovich A, Medina L, Piura B, Segal S, Huleihel M. Regulation of ovarian carcinoma SKOV-3 cell proliferation and secretion of mmps by autocrine IL-6. Anticancer Res. 2007;27(1A):267-72.
16. Terada T, Iwai M, Kawakami S, Yamashita F, Hashida M. Novel PEG-matrix metalloproteinase-2 cleavable peptide-lipid containing galactosylated liposomes for hepatocellular carcinoma-selective targeting. J Control Release. 2006;111(3):333-42.
17. Hatakeyama H, Akita H, Kogure K, Oishi M, Nagasaki Y, Kihira Y, et al. Development of a novel systemic gene delivery system for cancer therapy with a tumor-specific cleavable PEG-lipid. Gene Ther. 2007;14(1):68-77.
18. Hatakeyama H, Akita H, Ito E, Hayashi Y, Oishi M, Nagasaki Y, et al. Systemic delivery of sirna to tumors using a lipid nanoparticle containing a tumor-specific cleavable PEG-lipid. Biomaterials. 2011;32(18):4306-16.
19. Mok H, Bae KH, Ahn C-H, Park TG. PEGylated and mmp-2 specifically depegylated quantum dots: comparative evaluation of cellular uptake. Langmuir. 2009;25(3):1645-50.
20. Narayanan S, Binulal NS, Mony U, Manzoor K, Nair S, Menon D. Folate targeted polymeric 'green' nanotherapy for cancer. Nanotechnology. 2010;21(28):285107.
21. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials. 2008;29(33):4429-38.
22. Gullotti E, Yeo Y. Beyond the imaging: limitations of cellular uptake study in the evaluation of nanoparticles. J Control Release. 2012;164(2):170-6.
23. Lee H, Rho J, Messersmith PB. Facile conjugation of biomolecules onto surfaces via mussel adhesive protein inspired coatings. Adv Mater. 2009;21(4):431-4.
24. Lee H, Dellatore SM, Miller WM, Messersmith PB. Mussel-inspired surface chemistry for multifunctional coatings. Science. 2007;318(5849):426-30.
25. Zhang M, Zhang X, He X, Chen L, Zhang Y. A self-assembled polydopamine film on the surface of magnetic nanoparticles for specific capture of protein. Nanoscale. 2012;4(10):3141-7.
26. Ni K, Lu H, Wang C, Black KCL, Wei D, Ren Y, et al. A novel technique for in situ aggregation of gluconobacter oxydans using bio-adhesive magnetic nanoparticles. Biotechnol Bioeng. 2012;109(12):2970-7.
27. Tsai WB, Chen WT, Chien HW, Kuo WH, Wang MJ. Poly(dopamine) coating of scaffolds for articular cartilage tissue engineering. Acta Biomater. 2011;7(12):4187-94.
28. Ryou MH, Lee YM, Park JK, Choi JW. Mussel-inspired polydopamine-treated polyethylene separators for high-power li-ion batteries. Adv Mater. 2011;23(27):3066-70.
29. Lu L, Li QL, Maitz MF, Chen JL, Huang N. Immobilization of the direct thrombin inhibitor-bivalirudin on 316l stainless steel via polydopamine and the resulting effects on hemocompatibility in vitro. J Biomed Mater Res A. 2012;100(9):2421-30.
30. Kang K, Choi IS, Nam Y. A biofunctionalization scheme for neural interfaces using polydopamine polymer. Biomaterials. 2011;32(27):6374-80.
31. Xu P, Gullotti E, Tong L, Highley CB, Errabelli DR, Hasan T, et al. Intracellular drug delivery by poly(lactic-co-glycolic acid) nanoparticles, revisited. Mol Pharm. 2009;6(1):190-201.
32. Zhang Y, So MK, Rao J. Protease-modulated cellular uptake of quantum dots. Nano Lett. 2006;6(9):1988-92.
33. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7(6):743-8.
34. Lee S, Cha EJ, Park K, Lee SY, Hong JK, Sun IC, et al. A near-infrared-fluorescence-quenched gold-nanoparticle imaging probe for in vivo drug screening and protease activity determination. Angew Chem Int Ed Engl. 2008;47(15):2804-7.
35. Amoozgar Z, Park J, Lin Q, Yeo Y. Low molecular-weight chitosan as a pH-sensitive stealth coating for tumor-specific drug delivery. Mol Pharm. 2012;9(5):1262-70.
36. Berry CC. Intracellular delivery of nanopartides via the HIV-1 tat pepticle. Nanomedicine. 2008;3(3):357-65.
37. Sood AK, Fletcher MS, Coffin JE, Yang M, Seftor EA, Gruman LM, et al. Functional role of matrix metalloproteinases in ovarian tumor cell plasticity. Am J Obstet Gynecol. 2004;190(4):899-909.
38. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev. 2008;60(4-5):548-58.
39. Nam YS, Park JY, Han SH, Chang IS. Intracellular drug delivery using poly(d, l-lactide-co-glycolide) nano- particles derivatized with a peptide from a transcriptional activator protein of HIV-1. Biotechnol Lett. 2002;24(24):2093-8.
40. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci U S A. 2001;98(15):8786-91.
41. Koch AM, Reynolds F, Merkle HP, Weissleder R, Josephson L. Transport of surface-modified nanoparticles through cell monolayers. ChemBioChem. 2005;6(2):337-45.
42. Tong R, Cheng J. Paclitaxel-initiated, controlled polymerization of lactide for the formulation of polymeric nanoparticulate delivery vehicles. Angew Chem Int Ed Engl. 2008;47(26):4830-4.